Clinical Trials
19
Active:3
Completed:7
Trial Phases
3 Phases
Phase 1:8
Phase 2:10
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 2
10 (52.6%)Phase 1
8 (42.1%)Phase 3
1 (5.3%)Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Phase 2
Not yet recruiting
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: 50 mg UsnoflastDrug: 75 mg UsnoflastDrug: Placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT07023835
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Phase 1
Not yet recruiting
- Conditions
- Cholestatic Liver Disease
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06825559
- Locations
- 🇺🇸
Zydus Site US001, Indianapolis, Indiana, United States
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Phase 3
Recruiting
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06427395
- Locations
- 🇺🇸
Zydus US007, Birmingham, Alabama, United States
🇺🇸Zydus US013, Los Angeles, California, United States
🇺🇸Zydus US011, Pasadena, California, United States
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
Phase 2
Terminated
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05211284
- Locations
- 🇺🇸
Zydus US004, Birmingham, Alabama, United States
🇺🇸Zydus US005, La Jolla, California, United States
🇺🇸Zydus US006, San Francisco, California, United States
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Phase 2
Completed
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 196
- Registration Number
- NCT05133336
- Locations
- 🇺🇸
Zydus US007, Birmingham, Alabama, United States
🇺🇸Zydus US021, Tucson, Arizona, United States
🇺🇸Zydus US013, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found